Detalhe da pesquisa
1.
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Ann Oncol
; 34(2): 173-185, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414192
2.
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Ann Oncol
; 31(4): 507-516, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32139298
3.
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Ann Oncol
; 31(11): 1536-1544, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861806
4.
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
Ann Oncol
; 29(suppl_1): i20-i27, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29462255
5.
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Ann Oncol
; 29(8): 1701-1709, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29905778
6.
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
Ann Oncol
; 28(12): 3037-3043, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950351
7.
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ann Oncol
; 27(3): 423-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26768165
8.
Analysis of liver-directed therapies in U.S. cancer patients.
Curr Oncol
; 22(6): e457-61, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26715883
9.
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Br J Cancer
; 108(4): 762-5, 2013 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23322195
10.
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
ESMO Open
; 8(6): 102065, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37988950
11.
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ann Oncol
; 27(7): 1363, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27240994
12.
Innovative Clinical Trials: The LUNG-MAP Study.
Clin Pharmacol Ther
; 97(5): 488-91, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25676724
13.
Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
Cell Death Differ
; 21(7): 1160-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24769731
14.
A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.
Lung Cancer
; 81(3): 416-421, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23849982